Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous; 500 mg/vial) |
| Drug Class | Insulin-like growth factor-1 receptor inhibitors |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For the treatment of thyroid eye disease.
Summary
- Teprotumumab (Tepezza) is indicated for the treatment of thyroid eye disease.
- A total of 3 systematic reviews/meta-analyses were reviewed, providing insights into the efficacy and safety profile of teprotumumab in comparison to other treatments for thyroid eye disease.
- According to a Bayesian network meta-analysis, teprotumumab was found to be more efficacious than mycophenolate plus intravenous glucocorticoids (IVGCs), mycophenolate, rituximab, azathioprine, IVGCs alone, orbital radiotherapy and oral glucocorticoids in treating active moderate-to-severe Graves' orbitopathy; it also showed superior results in reducing proptosis compared with IVGCs.
- No significant difference was observed between teprotumamub and rituximab or orbital radiotherapy regarding changes in diplopia grade according to one study; however due to limited patient data on teprotomamub use this may not become standard first-line therapy for active moderate-to-severe Graves' orbitopathy yet.
- Another review suggested that while various interventions including teportimumamb showed significantly better improvement than no treatment at all for Graves’ ophthalmopathy patients; high heterogeneity among studies made robust recommendations difficult without further large randomized controlled trials or individual participant data meta-analyses.
- One study highlighted that clinical trials have shown an 83% proptosis response rate with Tepezza, along with improvements in the clinical activity score and quality of life, when compared to placebo. Common adverse reactions included muscle spasms, nausea, alopecia, diarrhea, fatigue, hyperglycemia, hearing impairment, dysgeusia, headache, and dry skin. However, overall, it was well tolerated by patients suffering from Thyroid Eye Disease.
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Tepezza (teprotumumab-trbw) Prescribing Information. | 2021 | Horizon Therapeutics USA Inc., Lake Forest, IL |
Systematic Reviews / Meta-Analyses
| Document Title | Year | Source |
|---|---|---|
| Comparative effectiveness of different treatment modalities for active, moderate-to-severe Graves' orbitopathy: a systematic review and network meta-analysis. | 2022 | Acta ophthalmologica |
| Treatment strategies for Graves’ ophthalmopathy: a network meta-analysis. | 2020 | British Journal of Opthamology |
| Teprotumumab for the treatment of thyroid eye disease. | 2020 | Expert review of clinical immunology |
Clinical Practice Guidelines
| Document Title | Year | Source |
|---|---|---|
| The 2021 European Group on Graves’ orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves’ orbitopathy. | 2021 | European Journal of Endocrinology |